Objective To research expression and clinical significance by G protein-coupled receptor 30 (GPR30) in pathological breast tissue of estrogen receptor negative breast cancer patients. Methods A total of 123 pathological samples of breast cancer patients were taken into immumohistochemical staining to observe expression of GPR30. Results GPR30 was shown in 63.41% of breast cancer patients, and patients with ER(+) had expression rate as 64.29%. TAM treatment showed drug resistance expression rate as 69.23%. Conclusion GPR30 contains important effects in endocrinotherapy for estrogen receptor negative breast cancer.%目的：研究 G 蛋白偶联受体30(GPR30)在雌激素受体阴性乳腺癌患者乳腺病理组织中的表达情况及临床意义。方法123例乳腺癌患者的病理标本，进行免疫组化染色，观察 GPR30的表达情况。结果GPR30表达于63.41%的乳腺癌患者中， ER(+)患者表达率64.29%，其中 TAM 治疗耐药表达率高达69.23%。结论GPR30在雌激素受体阴性的乳腺癌内分泌治疗中具有重要作用。
展开▼
